Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
Savaiano DA, et al
Published in Nutrition Journal
Methodology
Randomized, double-blind, placebo-controlled trial of escalating-dose RP-G28 over 35 days in adults with lactose intolerance, with symptom scoring after lactose challenge, hydrogen breath testing and post-treatment dairy intake.
Key Findings
A 35-day escalating course of the galacto-oligosaccharide RP-G28 reduced abdominal pain and other lactose intolerance symptoms after lactose challenge and increased subsequent dairy consumption, consistent with adaptive shifts in colonic lactose-fermenting bacteria.
Conclusions
RP-G28 appears to be a potentially useful approach for improving lactose digestion and LI symptoms.
Limitations
Moderate sample (n=85), short post-treatment follow-up, subjective symptom endpoints, and sponsorship by the product developer.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Funded by Ritter Pharmaceuticals, developer of RP-G28.
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.